



COVID-19 Pharmacy Program Emergency Response

The MassHealth Pharmacy Program, in coordination with agencies across the Executive Office of Health and Human Services, has released guidance in response to the new coronavirus - Coronavirus Disease 2019 (COVID-19). Please see below for additional information.

Providers with questions about the COVID-19 Pharmacy Program Emergency Response can contact the MassHealth Drug Utilization Review Program at (800) 745-7318.

Information regarding coverage of COVID-19 at home antigen self-test kits:

- Effective January 14, 2022, the following at home antigen self-test kits will be available without prior authorization within listed quantity limits and added to the MassHealth Non-Drug Product List.
 - Binaxnow – PA > 8 tests/28 days
 - Flowflex – PA > 8 tests/28 days
 - lhealth – PA > 8 tests/28 days
 - Inteliswab – PA > 8 tests/28 days
 - Quickvue – PA > 8 tests/28 days
- Effective March 21, 2022, the following at home antigen self-test kits will be available without prior authorization within listed quantity limits and added to the MassHealth Non-Drug Product List.
 - Carestart – PA > 8 tests/28 days
 - On-Go – PA > 8 tests/28 days

Information regarding coverage of COVID-19 treatment and preventative therapies:

- Effective October 22, 2020, the following agent was available only in an inpatient hospital setting and added to the MassHealth Drug List on December 13, 2020.
Effective December 30, 2021, the following agent will be available in both inpatient and outpatient hospital.
Effective February 7, 2022, the following agent will require prior authorization for outpatient use and will no longer be restricted to the health care professional who administers the drug. Please note, remdesivir was available through the federal Emergency Use Authorization (EUA) from May 1, 2020 to October 21, 2020.
 - Veklury (remdesivir) – PA
- Effective August 23, 2021, the following agent will be available without prior authorization and added to the MassHealth Drug List on September 20, 2021 for members 16 years old and above. Please note, Comirnaty is still available through the federal EUA from May 10,

2021 for members ages 12 to 15 years of age and EUA from October 29, 2021 for members 5 to 11 years of age.

- Comirnaty (COVID-19 Pfizer vaccine for members ≥ 16 years of age)
- Comirnaty (Pfizer COVID-19 vaccine for members ≥ 16 years of age)

- Effective January 31, 2022, the following agent will be available without prior authorization and added to the MassHealth Drug List on February 7, 2022.

Please note, Moderna COVID-19 vaccine was available through the federal EUA from December 18, 2020 to January 30, 2022.

- Spikevax (Moderna COVID-19 vaccine for members ≥ 18 years of age)
- Spikevax (COVID-19 Moderna vaccine for members ≥ 18 years of age)

- Effective May 10, 2022, the following agent will be available without prior authorization in the hospital setting and added to the MassHealth Drug List on June 27, 2022, for members 18 years old and above. Please note, Olumiant is still available through the federal EUA from November 19, 2020, for members two to less than 18 years of age.

- Olumiant (baricitinib for members ≥ 18 years of age) ^{COVID H}

- During the emergency declaration period, the cost of the therapies for treatment and prevention of COVID-19 listed below is covered by the federal government. Products are available through the Massachusetts Department of Public Health (DPH). Please check with DPH for availability. For information on coverage and payment for administration, please refer to the appropriate All Provider Bulletins below. For information on appropriate use, including specific variants and resistance, of the therapies listed below please refer to guidance from the Food and Drug Administration (FDA) www.fda.gov. Effective for the dates listed below, the following therapies for treatment and prevention of COVID-19 are available through the federal Emergency Use Authorization (EUA)*.

- Actemra (tocilizumab COVID EUA – June 24, 2021) †
- bamlanivimab, administered with etesevimab (COVID EUA – February 9, 2021) ‡
- bebtelovimab (COVID EUA – February 11, 2022)
- Comirnaty (Pfizer COVID-19 vaccine COVID EUA – May 10, 2021 for members 12 to 15 years of age)
- Comirnaty (COVID-19 Pfizer vaccine COVID EUA – May 10, 2021 for members 12 to 15 years of age)
- Comirnaty (Pfizer COVID-19 vaccine COVID EUA – October 29, 2021 for members 5 to 11 years of age)
- Comirnaty (COVID-19 Pfizer vaccine COVID EUA – October 29, 2021 for members 5 to 11 years of age)
- Comirnaty (Pfizer COVID-19 vaccine COVID EUA – June 17, 2022 for members 6 months to 4 years of age)
- Comirnaty (COVID-19 Pfizer vaccine COVID EUA – June 17, 2022 for members 6 months to 4 years of age)
- Evusheld (tixagevimab/cilgavimab COVID EUA – December 8, 2021)
- etesevimab, administered with bamlanivimab (COVID EUA – February 9, 2021) ‡
- Janssen COVID-19 Vaccine (COVID EUA – February 27, 2021)
- molnupiravir (COVID EUA – December 23, 2021)

- Olumiant (baricitinib COVID EUA – November 19, 2020 for members 2 to 17 years of age) †
- Paxlovid (nirmatrelvir/ritonavir COVID EUA – December 22, 2021)
- Regen-Cov (casirivimab, administered with imdevimab COVID EUA – November 21, 2020) ‡
- Regen-Cov (imdevimab, administered with casirivimab COVID EUA – November 21, 2020) ‡
- Spikevax (Moderna COVID-19 vaccine COVID EUA – June 17, 2022 for members 6 months to 17 years of age)
- Spikevax (COVID-19 Moderna vaccine COVID EUA – June 17, 2022 for members 6 months to 17 years of age)
- sotrovimab (COVID EUA – May 26, 2021) §

* Displayed EUA date corresponds to the original EUA date. For additional EUA approval dates, please refer to FDA guidance.

† For use under the EUA, this agent is available only in an inpatient hospital setting.

‡ As of January 24, 2022, this agent is not currently authorized for use in any U.S. region due to the high frequency of the Omicron variant.

§ As of April 5, 2022, this agent is not currently authorized for use in any U.S. region due to the high frequency of the Omicron BA.2 sub-variant.

Mass.Gov COVID-19 Webpage:

Information on Governor Baker’s State of Emergency announcements by the Executive Office of Health and Human Services, and other important links:

<https://www.mass.gov/resource/information-on-the-outbreak-of-coronavirus-disease-2019-covid-19>

MassHealth COVID-19 Provider Webpage:

Information on MassHealth’s response to COVID-19. Includes updated bulletins, pharmacy facts, and answers to frequently asked questions.

<https://www.mass.gov/info-details/masshealth-coronavirus-disease-2019-covid-19-providers>

Pharmacy Program Facts and Other Information for Pharmacies Regarding COVID-19:

Pharmacy Facts 141: Updates Related to Coronavirus Disease 2019 (COVID-19) Effective March 14, 2020:

<https://www.mass.gov/doc/pharmacy-facts-141-march-12-2020-0/download>

Pharmacy Facts 142: Additional Updates Related to Coronavirus Disease 2019 (COVID-19) Effective Immediately:

<https://www.mass.gov/doc/pharmacy-facts-no-142-march-20-2020-0/download>

Pharmacy Facts 143: Coronavirus Disease 2019 (COVID-19) and New Policies on Chloroquine and Hydroxychloroquine—Effective for Dates of Service on or after March 26, 2020:

<https://www.mass.gov/doc/pharmacy-facts-143-march-25-2020-0/download>

Pharmacy Facts 145: Additional Updates Related to Coronavirus Disease 2019 (COVID-19) provides guidance on how pharmacies should bill for home delivery, and updated information for pharmacies that provide durable medical equipment (DME) including DME prior authorization flexibilities.

<https://www.mass.gov/doc/pharmacy-facts-145-april-28-2020-0/download>

Pharmacy Facts 147: Additional Updates for Pharmacies Serving Health Safety Net Patients provides guidance for how pharmacies should submit claims for Health Safety Net (HSN) patients in light of new flexibilities that temporarily allow patients who are unable to receive their medications from their regular (HSN) provider to have those prescriptions filled by any pharmacy in the MassHealth network.

<https://www.mass.gov/doc/pharmacy-facts-147-may-13-2020/download>

Pharmacy Facts 150: Additional Updates Related to Coronavirus Disease 2019 (COVID-19) ends several temporary policy changes made in response to COVID-19, including early refills and some prior authorization flexibilities.

<https://www.mass.gov/doc/pharmacy-facts-150-july-13-2020-0/download>

Pharmacy Facts 154: Additional Update Related to Coronavirus Disease 2019 (COVID-19) ends a policy change made during the COVID-19 pandemic regarding albuterol inhaler prescribing requirements.

<https://www.mass.gov/doc/pharmacy-facts-154-october-7-2020-0/download>

Pharmacy Facts 155: Provides guidance on additional flexibilities for pharmacy coverage and billing for individuals who are Health Safety Net patients.

<https://www.mass.gov/doc/pharmacy-facts-155-october-7-2020-0/download>

Pharmacy Facts 157: Additional Updates Related to Coronavirus Disease 2019 (COVID-19) allows pharmacists to dispense up to a 365-day supply of drugs used for family planning if requested by a MassHealth member or that member's prescriber.

<https://www.mass.gov/doc/pharmacy-facts-157-december-1-2020-0/download>

Pharmacy Facts 160: The first COVID-19 vaccine product received Emergency Use Authorization (EUA) by the U.S. FDA on December 11, 2020, and a second product received EUA on December 18, 2020. MassHealth will cover the vaccines for members in MassHealth Standard, CommonHealth, Family Assistance, CarePlus, Children's Medical Security Plan, and Health Safety Net.

<https://www.mass.gov/doc/pharmacy-facts-160-january-22-2021-0/download>

Pharmacy Facts 162: COVID Vaccine Billing Information outlines the MassHealth rates of payment for COVID-19 vaccines and provides guidance on submitting claims for the vaccines.

<https://www.mass.gov/doc/pharmacy-facts-162-march-25-2021-0/download>

Pharmacy Facts 163: Removal of Prior Authorization (PA) Requirements for Chloroquine and Hydroxychloroquine removes the requirement that members must go through a PA process before chloroquine and hydroxychloroquine can be dispensed.

<https://www.mass.gov/doc/pharmacy-facts-163-may-7-2021-0/download>

Pharmacy Facts 165: Coronavirus Disease 2019 (COVID-19) Vaccine Billing Information, Including Vaccine Coverage Policy for MassHealth Limited Members provides a summary of MassHealth guidance related to billing for COVID-19 vaccines.

<https://www.mass.gov/doc/pharmacy-facts-165-may-24-2021-0/download>

Pharmacy Facts 167: Updates Related to Coronavirus Disease 2019 (COVID-19) Effective June 15, 2021 describes how MassHealth will continue to pay for prescription delivery and allow for additional exceptions to 30-day supply limitations following the end of the state of emergency in Massachusetts.

<https://www.mass.gov/doc/pharmacy-facts-167-june-15-2021-0/download>

Pharmacy Facts 170: MassHealth is providing updates on claim submission for members receiving a third Pfizer-BioNTech and Moderna COVID-19 vaccine dose, coverage for Apo-Varenicline, and a 10% rate add-on for durable medical equipment and oxygen and respiratory therapy (DME/OXY) providers. MassHealth has also included links to previously issued guidance about billing for COVID-19 vaccination.

<https://www.mass.gov/doc/pharmacy-facts-170-august-19-2021-0/download>

Pharmacy Facts 172: Amid the COVID-19 pandemic, the prescribing of ivermectin for the prevention or treatment of COVID-19 has increased. MassHealth has adopted immediate new policies for the prescribing and dispensing of ivermectin. There are also various updates to the MassHealth Drug List.

<https://www.mass.gov/doc/pharmacy-facts-172-september-20-2021-0/download>

Pharmacy Facts 176: MassHealth pharmacy coverage and billing information for COVID-19 oral antivirals.

<https://www.mass.gov/doc/pharmacy-facts-176-january-13-2022-2/download>

Pharmacy Facts 177: MassHealth Pharmacy Coverage of Over-the-Counter Diagnostic Antigen Tests for SARS-CoV-2.

<https://www.mass.gov/doc/pharmacy-facts-177-january-14-2022-0/download>

All Provider Bulletins:

All Provider Bulletin 289: MassHealth Coverage Reimbursement Policy for Service Related to Coronavirus Disease 2019 addresses lab services, access to telehealth, billing of home visits, 90-day supplies of medications, early refills, cost-sharing and referrals:

<https://www.mass.gov/doc/all-provider-bulletin-289-masshealth-coverage-and-reimbursement-policy-for-services-related-to/download>

All Provider Bulletin 291: MassHealth Coverage and Reimbursement Policy for Services Related to Coronavirus Disease 2019 (COVID-19) builds off of Bulletin 289 to create additional flexibilities including: relaxing referral requirements, further expanding HPE, allowing medication delivery and

waiving pharmacy signature requirements, and providing guidance for Emergency Services Program (ESP) and Mobile Crisis Intervention (MCI) Services:

<https://www.mass.gov/doc/all-provider-bulletin-291-masshealth-coverage-and-reimbursement-policy-for-services-related-0/download>

All Provider Bulletin 304: Coverage and Payment for Coronavirus Disease 2019 (COVID-19) Vaccine Administration, Testing, and Monoclonal Antibody Product Infusion provides guidance regarding coverage and payment for COVID-19 vaccines for the MassHealth and limited benefit populations. It also provides coverage and payment guidance regarding two monoclonal antibody therapies to treat COVID-19 as well as guidance on new testing codes.

<https://www.mass.gov/doc/all-provider-bulletin-304-coverage-and-payment-for-coronavirus-disease-2019-covid-19-vaccine-0/download>

All Provider Bulletin 307: Updated Payment Rates and Authorized Providers for Coronavirus Disease 2019 (COVID-19) Vaccine Administration supersedes portions of All Provider Bulletin 304 to provide updated information on payment for COVID-19 vaccine administration and to list additional providers who may bill for COVID-19 vaccine administration.

<https://www.mass.gov/doc/all-provider-bulletin-307-updated-payment-rates-and-authorized-providers-for-coronavirus-0/download>

All Provider Bulletin 312: Additional Authorized Vaccine Product and Antibody Treatment and Update to Authorized Providers and Coverage Policy for MassHealth Limited Members for Coronavirus Disease 2019 (COVID-19) Vaccine Administration adds the Johnson & Johnson COVID-19 vaccine as an authorized product and provides guidance on rates for the vaccine, lists additional providers who may bill MassHealth for vaccine administration, and requires providers to bill MassHealth for COVID-19 vaccines administered to MassHealth Limited members rather than the federal COVID-19 Uninsured Program portal.

<https://www.mass.gov/doc/all-provider-bulletin-312-additional-authorized-vaccine-product-and-antibody-treatment-and-0/download>

All Provider Bulletin 313: Updated Rates for Coronavirus Disease 2019 (COVID-19) Vaccine Administration updates the rates MassHealth will pay for COVID-19 vaccine administration for dates of service on or after April 1, 2021.

<https://www.mass.gov/doc/all-provider-bulletin-313-updated-rates-for-coronavirus-disease-2019-covid-19-vaccine-administration-0/download>

All Provider Bulletin 317: Update to Authorized Providers for Coronavirus Disease 2019 (COVID-19) Vaccine Administration permits acute treatment services providers, clinical stabilization services providers and dental providers to bill MassHealth for COVID-19 vaccine administration, in addition to all provider types previously identified as eligible in prior bulletins.

<https://www.mass.gov/doc/all-provider-bulletin-317-update-to-authorized-providers-for-coronavirus-disease-2019-covid-19-vaccine-administration-0/download>

All Provider Bulletin 318: Update about Monoclonal Antibody Treatment for Coronavirus Disease 2019 (COVID-19) supplements and updates All Provider Bulletins 304 and 312 and provides an update to the payment provisions for monoclonal antibody treatment for COVID-19.

<https://www.mass.gov/doc/all-provider-bulletin-318-update-about-monoclonal-antibody-treatment-for-coronavirus-disease-2019-covid-19-0/download>

All Provider Bulletin 319: Coverage and Reimbursement Policy Updates for Services Related to COVID-19 After the Termination of the State of Emergency retains certain flexibilities set to expire at the end of the Massachusetts state of emergency and describes certain additional flexibilities that will continue after the end of the state of emergency.

<https://www.mass.gov/doc/all-provider-bulletin-319-coverage-and-reimbursement-policy-updates-for-services-related-to-covid-19-after-the-termination-of-the-state-of-emergency-0/download>

All Provider Bulletin 320: Expiration of Temporary Extension of Timely Replies for Initial Notices of Overpayment during COVID-19 Emergency informs providers that the temporary extension for a provider to provide a written response to dispute an INOP will expire June 15, 2021, in conjunction with the end of the Massachusetts state of emergency.

<https://www.mass.gov/doc/all-provider-bulletin-320-expiration-of-temporary-extension-of-timely-replies-for-initial-notices-of-overpayment-during-covid-19-emergency-0/download>

All Provider Bulletin 321: Coverage and Reimbursement Policy for Services Related to Coronavirus Disease 2019 (COVID-19) Vaccine Counseling informs providers that MassHealth is introducing additional coverage for COVID-19 vaccine counseling services effective July 26, 2021.

<https://www.mass.gov/doc/all-provider-bulletin-321-coverage-and-reimbursement-policy-for-services-related-to-coronavirus-disease-2019-covid-19-vaccine-counseling-0/download>

All Provider Bulletin 322: Coverage for Third Dose of Pfizer-BioNTech and Moderna Coronavirus Disease 2019 (COVID-19) Vaccine for Immunocompromised Individuals announces that, effective August 12, 2021, MassHealth will cover the administration of the third dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines to individuals who qualify for the additional dose and are enrolled in MassHealth fee-for-service, the Primary Care Clinician (PCC) Plan, or a primary care accountable care organization (ACO).

<https://www.mass.gov/doc/all-provider-bulletin-322-coverage-for-third-dose-of-pfizer-biontech-and-moderna-coronavirus-disease-2019-covid-19-vaccine-for-immunocompromised-individuals-0/download>

All Provider Bulletin 326: Coverage for Monoclonal Antibodies for Treatment and Post-Exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) updates the coverage and payment provisions for monoclonal antibodies for treatment and post-exposure prophylaxis for COVID-19. This bulletin applies to members enrolled in MassHealth fee-for-service, the Primary Care Clinician (PCC) Plan, or a Primary Care Accountable Care Organization (ACO).

<https://www.mass.gov/doc/all-provider-bulletin-326-coverage-for-monoclonal-antibodies-for-treatment-and-post-exposure-prophylaxis-for-coronavirus-disease-2019-covid-19-0/download>

All Provider Bulletin 328: Coverage for Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccines announces that MassHealth will cover booster doses of the Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines consistent with the Emergency Use Authorizations (EUAs).

<https://www.mass.gov/doc/all-provider-bulletin-328-coverage-for-booster-doses-of-coronavirus-disease-2019-covid-19-vaccines-0/download>

All Provider Bulletin 330: MassHealth Coverage for Coronavirus Disease 2019 (COVID-19) Vaccines, including Pediatric Vaccines, and Monoclonal Antibodies announces that MassHealth will cover the administration of the Pfizer-BioNTech COVID-19 vaccine to children 5 through 11 years of age consistent with the EUA.

<https://www.mass.gov/doc/all-provider-bulletin-330-masshealth-coverage-for-coronavirus-disease-2019-covid-19-vaccines-including-pediatric-vaccines-and-mono-clonal-antibodies-0/download>

All Provider Bulletin 333: MassHealth Coverage for Coronavirus Disease 2019 (COVID-19) Vaccine Booster Doses including Pediatric Vaccines, and Monoclonal Antibodies consolidates MassHealth coverage policies for adult and pediatric vaccinations, including boosters, and monoclonal antibody treatments.

<https://www.mass.gov/doc/all-provider-bulletin-333-masshealth-coverage-for-coronavirus-disease-2019-covid-19-vaccine-booster-doses-0/download>

All Provider Bulletin 336: Coverage of and Payment for the Administration of (1) Tixagevimab Co-Packaged with Cilgavimab, and (2) Remdesivir in an Outpatient Setting.

<https://www.mass.gov/doc/all-provider-bulletin-336-coverage-of-and-payment-for-the-administration-of-1-tixagevimab-co-packaged-with-cilgavimab-and-2-remdesivir-in-an-outpatient-setting-0/download>

All Provider Bulletin 337: MassHealth Pharmacy Coverage of Over-the-Counter Diagnostic Antigen Tests for SARS-CoV-2 announces that, effective January 14, 2022, the FDA approved OTC COVID-19 at-home antigen self-test kits have been added to the MassHealth Non-Drug Product List and will be covered through the MassHealth pharmacy benefit.

<https://www.mass.gov/doc/all-provider-bulletin-337-masshealth-pharmacy-coverage-of-over-the-counter-diagnostic-antigen-tests-for-sars-cov-2-0/download>

All Provider Bulletin 341: Coverage of and Payment for the Administration of (1) Tixagevimab Co-Packaged with Cilgavimab, and (2) Bebtelovimab describes a revision to the emergency use authorization (EUA) that appeared in All Provider Bulletin 336 pertaining to the administration of tixagevimab co-packaged with cilgavimab. It also details coverage for the monoclonal antibody bebtelovimab, which the FDA granted EUA for on February 11, 2022.

<https://www.mass.gov/doc/all-provider-bulletin-341-coverage-of-and-payment-for-the-administration-of-1-tixagevimab-co-packaged-with-cilgavimab-and-2-bebtelovimab-0/download>

LTSS Provider Information:

Information for DME providers:

Durable Medical Equipment Bulletin 26: COVID-19 Related Administrative Flexibilities for Durable Medical Equipment Providers – Extension extends COVID-19 related flexibilities for providers of MassHealth-covered durable medical equipment. Some of the flexibilities described in the bulletin will extend until the end of the federal public health emergency, while others do not have an end date.

<https://www.mass.gov/doc/durable-medical-equipment-bulletin-26-covid-19-related-administrative-flexibilities-for-durable-medical-equipment-providers-extension/download>

Managed Care Bulletins:

Bulletin 22: Consolidates new COVID-19 related pharmacy requirements for MassHealth Accountable Care Partnership Plans (ACPPs) and Managed Care Organizations (MCOs):

<https://www.mass.gov/doc/managed-care-entity-bulletin-22-updated-coverage-and-payment-policies-0/download>

Bulletin 41: Contains updated policies for Accountable Care Partnership Plans (ACPPs) and Managed Care Organizations (MCOs) that align with certain coverage and payment policies of MassHealth's Fee-for-Service program, Primary Care Clinician (PCC) Plan, and Primary Care Accountable Care Organizations relating to pharmacy services, referrals, and payment:

<https://www.mass.gov/doc/managed-care-entity-bulletin-41-updated-pharmacy-coverage-policies-0/download>

Bulletin 49: Flu Vaccine Access and Birth Control Supply Flexibility makes changes to the out-of-network flu vaccine coverage and guidance on birth control supplies for Accountable Care Partnership Plans (ACPPs) and Managed Care Organizations (MCOs) to provide greater flexibility in providing care to MassHealth members:

<https://www.mass.gov/doc/managed-care-entity-bulletin-49-flu-vaccine-access-and-birth-control-supply-flexibility-0/download>

Bulletin 50: Coverage and Payment for Coronavirus Disease 2019 (COVID-19) Vaccine Administration, Testing, and Monoclonal Antibody Product Infusion provides guidance regarding coverage and payment for COVID-19 vaccines for the MassHealth members enrolled in an Accountable Care Partnership Plan (ACPPs), Managed Care Organization (MCOs), Senior Care Organization (SCOs) or One Care plan. It also provides coverage and payment guidance regarding two monoclonal antibody therapies to treat COVID-19 as well as guidance on new testing codes:

<https://www.mass.gov/doc/managed-care-entity-bulletin-50-coverage-and-payment-for-coronavirus-disease-2019-covid-19-0/download>

Bulletin 52: Update to Payment for Coronavirus Disease 2019 (COVID-19) Vaccine Administration, Update to Authorized Vaccine Providers, and New Mass Immunizer Providers requires managed care plans and PACE organizations to match the payment and coverage policies of MassHealth's fee-for-service program for COVID-19 vaccines, as described in All Provider Bulletin 307:

<https://www.mass.gov/doc/managed-care-entity-bulletin-52-update-to-payment-for-coronavirus-disease-2019-covid-19-vaccine/download>

Bulletin 57: Update to Payment for Coronavirus Disease 2019 (COVID-19) Vaccine Administration, Authorized Vaccine Providers, and Mass Immunizer Providers requires managed care plans to conform their coverage policies, including rates of payment, for COVID-19 vaccines with MassHealth's fee-for-service policies:

<https://www.mass.gov/doc/managed-care-entity-bulletin-57-update-to-payment-for-coronavirus-disease-2019-covid-19-vaccine-administration-authorized-vaccine-providers-and-mass-immunizer-providers-0/download>

Bulletin 62: Update to Authorized Providers and Payment for Coronavirus Disease 2019 (COVID-19) Vaccine Administration requires managed care entities to conform their coverage policies when providing COVID-19 vaccines as Medicaid services, including rates of payments, to match those in All Provider Bulletin 317:

<https://www.mass.gov/doc/managed-care-entity-bulletin-62-update-to-authorized-providers-and-payment-for-coronavirus-disease-2019-covid-19-vaccine-administration-0/download>

Bulletin 66: Coverage and Reimbursement Policy Updates for Services Related to COVID-19 After the Termination of the State of Emergency outlines certain MassHealth flexibilities implemented in response to the COVID-19 pandemic in 2020 that are being retained after the State of Emergency terminated in the Commonwealth. It also describes certain additional flexibilities and requirements that will continue after the end of the State of Emergency:

<https://www.mass.gov/doc/managed-care-entity-bulletin-66-coverage-and-reimbursement-policy-updates-for-services-related-to-covid-19-after-the-termination-of-the-state-of-emergency-0/download>

Bulletin 67: Coverage and Payment Policy for Services Related to COVID-19 Vaccine Counseling and 3rd Dose of Pfizer-BioNTech Vaccine and Moderna COVID-19 Vaccine for Immunocompromised Individuals, in accordance with All Provider Bulletin 321 and All Provider Bulletin 322, mandates managed care plans and PACE organizations to cover clinically appropriate, medically necessary COVID-19 vaccine counseling services and 3rd doses of Pfizer-BioNTech and Moderna for immunocompromised members:

<https://www.mass.gov/doc/managed-care-entity-bulletin-67-coverage-and-payment-policy-for-services-related-to-covid-19-vaccine-counseling-and-3rd-dose-of-pfizer-biontech-vaccine-and-moderna-covid-19-vaccine-for-immunocompromised-individuals-0/download>

Bulletin 69: Coronavirus Disease 2019 (COVID-19) Updated Guidance for Integrated Care Plans provides updated flexibilities and requirements related to COVID-19 and supersedes all prior guidance:

<https://www.mass.gov/doc/managed-care-entity-bulletin-69-coronavirus-disease-2019-covid-19-updated-guidance-for-integrated-care-plans/download>

Bulletin 73: Coverage for Monoclonal Antibodies for Treatment and Post-Exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) requires managed care plans to conform their coverage policies, including rates of payments, to match those in All Provider Bulletins 318 and 326, when providing monoclonal antibody products for treatment and post-exposure prophylaxis for COVID-19 as Medicaid services.

<https://www.mass.gov/doc/managed-care-entity-bulletin-73-coverage-for-monoclonal-antibodies-for-treatment-and-post-exposure-prophylaxis-for-coronavirus-disease-2019-covid-19-0/download>

Bulletin 77: Coverage and Payment Policy for Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccines, Pediatric Vaccines, and Monoclonal Antibody Treatments restates and consolidates MassHealth coverage requirements for adult and pediatric COVID-19 vaccinations and monoclonal antibody treatments.

<https://www.mass.gov/doc/managed-care-entity-bulletin-77-coverage-and-payment-policy-for-booster-doses-of-coronavirus-disease-2019-covid-19-vaccines-pediatric-vaccines-and-monoclonal-antibody-treatments-0/download>

Bulletin 80: Coverage of Over-the-Counter Diagnostic Antigen Tests for SARS-CoV-2 instructs managed care plans to institute certain policies to align with MassHealth's All Provider Bulletin 337, effective January 14, 2022.

<https://www.mass.gov/doc/managed-care-entity-bulletin-80-coverage-of-over-the-counter-diagnostic-antigen-tests-for-sars-cov-2-0/download>

Mass Immunizer Provider Bulletins:

Bulletin 1: Mass Immunizer Provider Requirements and Payment for Coronavirus Disease 2019 (COVID-19) Vaccine Administration provides guidance on MassHealth requirements for new mass immunizer providers and provides information on payment to these providers.

<https://www.mass.gov/doc/mass-immunizer-provider-bulletin-1-mass-immunizer-provider-requirements-and-payment-for-0/download>

Bulletin 2: Updated Rates for Coronavirus Disease 2019 (COVID-19) Vaccine Administration updates the rates of payment for COVID-19 vaccine administration on or after April 1, 2021 and requires providers to bill MassHealth for members with the MassHealth Limited benefit.

<https://www.mass.gov/doc/mass-immunizer-bulletin-2-updated-rates-for-coronavirus-disease-2019-covid-19-vaccine-administration-0/download>

General Reminders:

- **Emergency Overrides**

Consistent with 130 CMR 406.411(B) and to ensure MassHealth members do not experience gaps in care, pharmacists may initiate an emergency override if they encounter a rejected claim for a medication requiring prior authorization. MassHealth will pay the pharmacy for at least a 72-hour, nonrefillable supply of the drug. To obtain an emergency override, pharmacists should contact the Drug Utilization Review Unit at (800) 745-7318 during normal business hours. If outside of business hours, pharmacies may submit an emergency override claim with a value of "03" for Level of Service (field 418). After the prescription is adjudicated, the pharmacy should remove the "03" from the level of service field before the next fill.

- **Cost Sharing**

MassHealth reminds providers of those services for which MassHealth charges copayments, such as pharmacy services, that they "may not refuse services to any members who are unable to pay the copayment at the time service is provided" 130 CMR 450.130(G)(2).

Board of Registration in Pharmacy Guidance:

Recent news & announcements, including answers to COVID-19 frequently asked questions:

<https://www.mass.gov/orgs/board-of-registration-in-pharmacy>